Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology

CONCLUSIONS: No significant differences were detected between UH and CH groups. Prospective trials are needed to understand ICIs role in UH population.PMID:34334296 | DOI:10.1016/j.cllc.2021.06.013

Source: Clinical Lung Cancer - August 2, 2021 Category: Cancer & Oncology Authors: Sara Manglaviti Marta Brambilla Diego Signorelli Roberto Ferrara Giuseppe Lo Russo Claudia Proto Giulia Galli Alessandro De Toma Mario Occhipinti Giuseppe Viscardi Teresa Beninato Emma Zattarin Marta Bini Riccardo Lobefaro Giacomo Massa Achille Bottiglier Source Type: research